At baseline ( @ vs. @ mcg/mL ) and during follow-up -LSB- @ ( @-@ @ ) vs. @ ( @-@ @ ) mcg/mL , p < @ -RSB- , median adalimumab trough levels in patients with clinical or endoscopic recurrence were lower than in those who maintained remission .